Abstract Objective and design: The role of Thoracic Endovascular Repair (TEVAR) in chronic type B aortic dissection remains controversial and its mid-term success as an alternative to open repair or best medical therapy remains unknown. The aim of the present study was to provide a systematic review of mid-term outcomes of TEVAR for chronic type B aortic dissection. Materials and methods: Medline, trial registries, conference proceedings and article reference lists from 1950 to January 2011 were searched to identify case series reporting mid-term outcomes of TEVAR in chronic type B dissection. Data were extracted for review. Results: 17 studies of 567 patients were reviewed. The technical success rate was 89.9% (range 77.6e100). Mid-term mortality was 9.2% (46/499) and survival ranged from 59.1 to 100% in studies with a median follow-up of 24 months. 8.1% of patients (25/309) developed endoleak, predominantly type I. Re-intervention rates ranged from 0 to 60% in studies with a median follow-up of 31 months. 7.8% of patients (26/332) developed aneurysms of the distal aorta or continued false lumen perfusion with aneurysmal dilatation. Rare complications included delayed retrograde type A dissection (0.67%), aorto-oesophageal fistula (0.22%) and neurological complications (paraplegia 2/447, 0.45%; stroke 7/475, 1.5%). Conclusion: The absolute benefit of TEVAR over alternative treatments for chronic B-AD remains uncertain. The lack of natural history data for medically treated cases, significant heterogeneity in case selection and absence of consensus reporting standards for intervention are significant
obstructions to interpreting the mid-term data. High-quality data from registries and clinical trials are required to address these challenges. ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Introduction
The role of thoracic endovascular aortic repair (TEVAR) in complicated chronic type B aortic dissection (B-AD) remains controversial.
1e5 A recent expert consensus document concluded that medical therapy remains the best treatment for uncomplicated chronic B-AD. 6 This was supported by the INSTEAD (INvestigation of STEnt grafts in patients with type B Aortic Dissection) trial, which randomised patients with uncomplicated chronic B-AD to TEVAR with best medical therapy or to best medical therapy alone. The trial revealed no advantages in the rates of survival, aortic rupture or need for re-intervention of TEVAR over medical therapy at 2 years. 7 Intervention is justified in complicated chronic B-AD; in patients with significant aortic dilatation (maximum thoracic aortic diameter >5.5 mm), rapid aortic growth (>1 cm/year), the development of unrelenting pain, uncontrollable hypertension, end-organ ischaemia or aortic rupture. 6, 8 In these settings, TEVAR aims to prevent persistent perfusion of the false lumen (FL) with the resultant aortic expansion (estimated at 1e4.3 mm/year), which has been shown to increase the risk of aortic rupture and other complications. 8, 9 Once the aortic diameter exceeds 60 mm, the risk of FL rupture is estimated at 30% per annum. 10, 11 The appropriateness of TEVAR for chronic dissection has been questioned due to the established nature of the false lumen and the presence of multiple fenestrations that decrease the likelihood of complete FL thrombosis. 6 Other areas of uncertainty include the length of aortic coverage required to accomplish successful treatment. Although favourable perioperative outcomes and one-year survival rates have been demonstrated for TEVAR compared to open surgery, the long-term outcomes of TEVAR remain unknown. 12 The outcomes of TEVAR have been reported in mixed pathology comprising both acute and chronic dissections, 13, 14 as well as exclusively for acute type B dissection, 15 but few separate data exist to define the performance of TEVAR exclusively in the setting of chronic type B dissection. This is despite evidence that acute B-AD and chronic B-AD behave differently following endovascular intervention and consequently have different outcomes. 13 Furthermore, those dissections with a strong genetic aetiology may have different outcomes to those with a degenerative aetiology. 16 Figure 1 PRISMA flow diagram depicting search strategy used. The mid-term outcomes of TEVAR in chronic B-AD are critical to understanding the success of treatment in a disease process that continues to evolve even after surgical or endovascular intervention. The aim of the present study was to provide the first focussed systematic review of midterm outcomes of TEVAR for chronic type B aortic dissection.
Methods

Study selection
An electronic search was performed using the Embase and Medline databases from 1950 to January 2011. The free-text and MeSH search terms "chronic," "aortic," "dissection," "aortic syndrome," and "endovascular" were used in combination with the Boolean operators AND or OR. The reference lists of articles obtained were also searched to identify further relevant citations. Finally, the search included the Current Controlled Trials Register (www. controlled-trials.com), the DARE database and the Cochrane Database of Controlled Trials. The literature review conformed to PRISMA statement standards. 17, 18 Quantitative meta-analysis was not performed due to the heterogeneity of study design, treatment methodology and patient population in studies that were included in qualitative review. The minimum inclusion criteria specified data concerning early or mid-term mortality after TEVAR for chronic type B dissection in 10 or more patients (Fig. 1 ).
Definitions
Chronic type B aortic dissection was defined by presentation after 14 days of symptom onset. Technical success indicated satisfactory closure of the primary entry tear, endograft deployment without type I or III endoleak or the absence of open surgical conversion or death within 24 h of the operation. 19 'Early' and 'mid-term' outcomes were defined according to reporting criteria as within 30 days of operation, and from 30 days to 5 years after the operation, respectively. 19 
Data extraction
Data were extracted regarding demographics, co-morbidity, case selection (indication, maximum reported descending aortic diameter, time from symptom onset, proportion of symptomatic patients, true lumen:false lumen ratio, primary entry tear location, number and location of fenestrations, operative details, technical success, and early and mid-term outcomes (endoleak, subsequent aortic expansion, retrograde dissection, aortic rupture, stroke, paraparesis or paraplegia, 30-day and mid-term mortality, length of stay and freedom from re-intervention). Data were collected by two authors (ST and AK); discrepancies were resolved by discussion with mutual consensus.
Results
The literature search identified 97 abstracts, of which 16 were excluded for reporting acute B-AD. 81 full-text articles were scrutinised. 26 were excluded for featuring less than 10 cases of chronic B-AD, 36 were excluded for reporting a mixed cohort of acute B-AD and chronic B-AD without data pertaining exclusively to treatment of chronic B-AD, and 2 were review articles without original data. Based on these entry and exclusion criteria, original data from 17 articles were reviewed, which encompassed the endovascular management of 567 patients described in 1 randomised controlled trial, 14 retrospective cohort studies and 2 prospective cohort studies. 2,4,5,7,20e32 Case selection Patient demographics, presenting features and comorbidities are shown in Table 1 . The mean age was 60 years; 82% were male and 40% initially presented symptomatically. The most common co-morbidities were hypertension (79.4%), coronary artery disease (20.6%), prior aortic surgery (18.5%) and chronic respiratory impairment (18.2%). 5.5% of all patients were reported as having the Marfan syndrome. The median time from dissection to intervention was 18 months (range 20 dayse129 months).
The most common stated indication for intervention was a maximum descending aortic diameter exceeding 50 mm (10/17, 58.8%). Eleven studies listed more than one indication for TEVAR but of these, only four studies listed the proportions for each indication. Many studies predominantly reported the results of TEVAR in asymptomatic patients with chronic B-AD (166/277, 59.9%). Other indications included rapid aortic enlargement (>10 mm/year), proven or imminent aortic rupture, refractory chest pain, refractory hypertension and end-organ ischaemia. No data were available regarding the number and location of fenestrations, pre-operative true lumen/false lumen ratio, or the level at which maximum pre-operative descending thoracic aortic diameter was reported.
Technical aspects and success
Procedural details and technical success rates are shown in Table 2 . The Talent stent-graft (Medtronic, Santa Rosa, CA, USA) was the most common employed (10/17, 58.8%). A median of 1.56 devices (range 1e3) were used per patient with a graft lengths of 60e359 mm (median 131.7 mm). The technical success rate was 89.9% (range 77.6e100), with a median operating time 132.9 min (range 20e380). 4/17 studies reported that supra-aortic branch revascularisation (e.g. carotid-subclavian bypass) was performed in 21.7% of patients (28/129).
Early clinical success
'Early' clinical success was defined by outcomes within the first 30 postoperative days ( Table 3 ). The average duration of intensive care and inpatient stay were 3.3 and 10 days respectively. The overall 30-day mortality was 3.2% (18/ 567). Endoleak was the commonest early complication (11.7%, 38/325). In studies that reported endoleaks according to subtype, the global incidence of endoleak was 15.8% (37/234), 15.4% (36/234) type I and 0.43% (1/234) type II. The incidence of early retrograde dissection was 1.6% (3/187) and that for peri-procedural aortic rupture was 2.3% (7/303). Neurological complications were rare; the incidence of stroke was 0.82% (4/489), and the reported incidence of paraplegia or paraparesis was 0.43% (2/462).
Mid-term clinical success
Mid-term clinical success was defined by outcomes between 30 days and 5 years postoperatively (Table 4) ; no studies provided outcome data beyond this point. The median length of follow-up was 26.1 months (range 0.6e97), during which the all studies used computed tomography angiography (CTA) as their imaging modality of choice; with a few studies additionally employing magnetic resonance angiography (MRA) and trans-oesophageal echocardiography (TOE). The late all-cause mortality rate was 9.2% (46/499). Survival rates ranged from 59.1 to 100% in studies with a median follow-up of 24 months (Fig. 2) . The mid-term aortic-related mortality was derived from those studies that specifically reported it as 4.2% (18/425). Absolute reintervention rates ranged from 0 to 60% in studies with a median follow-up of 31 months. Three cases of delayed retrograde type A dissection were reported (0.67%), 2,7,26 1 case of aorto-oesophageal fistula was reported (0.22%), 29 and mid-term neurological complications were rare (paraplegia 2/447, 0.45%; stroke 7/475, 1.5%). Mid-term health economic data were not available.
The commonest delayed complication was the development of aneurysms of the distal aorta or continued false lumen perfusion with aneurysmal dilatation (26/332, 7.8%) (Fig. 3) . The mid-term incidence of endoleak was 8.1% (25/ 309) (Fig. 4) . In studies which reported endoleak according to subtype, type I endoleak was most common and was reported in 7.4% (23/309) of patients, compared to type II and type III endoleak which were each reported in 0.3% (1/ 309) of patients. Fewer studies reported subgroup definitions of type I endoleak. In these reports, mid-term type I endoleaks were predominantly proximal; the incidence of type Ia endoleak was 5.2% [12/232] compared to 0.43% [1/ 232] incidence of type Ib endoleak. Delayed aortic rupture was reported in 3.0% (12/403) . No studies reported whether rupture occurred within or distal to the stented segment, or following persistent false lumen perfusion.
Rates of complete false-lumen (FL) thrombosis ranged from 38.5 to 100% (median 85.7%) in studies with a median follow-up of 17 months 2, 4, 5, 7, 20, 21, 23, 24, 26, 28, 30, 32 and appeared to have been reported in a bimodal manner (Fig. 5) . However, reporting was variable in completeness and the total number of patients in which results were available was low. Studies reporting mid-term follow-up of the true lumen:false lumen ratio observed reduction in false lumen diameter in 79.4% (27/34), FL expansion occurred in 15% (9/60), and true lumen (TL) expansion in 66.1% (41/62) of patients followed-up for a median of 30 months. 4, 23, 26, 28, 29 There was heterogeneity in the manner in which changes in aortic diameter were reported, with different numbers of studies reporting growth, shrinkage or stasis in the maximum diameter of the thoracic aorta. Although the denominator for each group was therefore different, summary statistics revealed that expansion in the overall maximum diameter of the thoracic aorta was reported in 2.5% (1/40), reduction in the overall 
Discussion
Chronic type B dissection poses unique challenges to the application of endovascular technology, yet the mid-term outcomes of TEVAR remain ill defined. Thickening of the dissection septum, which usually begins with symptom onset, progresses with the chronicity of B-AD, and may be less amenable to successful endografting than in the acute phase. Consequently, chronic B-AD exhibits a lesser degree of aortic remodelling than is seen in acute B-AD. 23, 28, 33 False-lumen thrombosis is key to ensuring long-term clinical success in chronic B-AD, which mandates extensive aortic coverage. 23 In the present review the length of stent-grafts deployed varied widely, from 60 to 359 mm (mean 131.7 mm). This diversity in aortic coverage, alongside variation in case selection and reporting standards, may have contributed to the variation seen in midterm outcomes, which were heterogeneous.
Early outcomes
The mean 30-day mortality after TEVAR for chronic B-AD in the present study was 3.2%, which was similar to that reported by Eggebrecht et al. in a comparative metaanalysis demonstrating lower 30-day mortality after TEVAR for chronic B-AD compared to TEVAR for acute B-AD (chronic 3.2% vs. acute 9.8%). 13 The rate of early endoleak reported after TEVAR for chronic B-AD in this series was 11.1%, which was the most common early complication observed. 
Technical success and feasibility
The technical success rates reported for TEVAR were reasonable, but remain lower than those reported previously in reviews of acute B-AD (chronic 89.9% vs. acute 95%). 15 Others have noted no significant difference in the rate of technical success after TEVAR for acute and chronic B-AD (acute 93.4 AE 0.9%, chronic 96.0 AE 1.2%, p Z 0.381). 
Mid-term outcomes
Although aneurysm-related mortality was not specifically reported in many studies, mid-term aortic complications were an important feature of TEVAR for chronic B-AD. Previous reviews have suggested that up to 20% of patients with chronic B-AD require re-intervention for established or imminent rupture in the follow-up period after TEVAR with optimal medical treatment. 10 In the present review absolute re-intervention rates were diverse, ranging from 0 to 60% in studies with a median follow-up of 31 months. The commonest causes of delayed morbidity were aneurysmal dilatation of the distal aorta or false lumen (26/332, 7.8%) and mid-term endoleak (25/309, 8.1%), which appeared to increase steadily during follow-up (Figs. 3 and 4) .
The majority of endoleaks were proximal Type I, and delayed aortic rupture was reported in 3.0% (12/403), but no studies reported whether rupture occurred within or distal to the stented segment, or following persistent false Figure 2 Scatterplot to illustrate mid-term survival after TEVAR for chronic B-AD. Each of the 10 studies is represented by a single datapoint. The sample size of each study (range 14e84) is reflected by the size of its respective datapoint. The reference number of each study is also displayed within the respective datapoint. Figure 3 Scatterplot to illustrate mid-term incidence of distal aneurysmal expansion of the thoracic aorta after TEVAR for chronic B-AD. Each of the 9 studies is represented by a single datapoint. The sample size (range 10e84) of each study is reflected by the size of its respective datapoint. The reference number of each study is also displayed within the respective datapoint.
lumen perfusion. The increased risk of rupture compared to acute B-AD may be attributable to the decreased mobility of the dissection flap over time, the greater likelihood of consequent aneurysmal dilatation and the relative lack of aortic remodelling in chronic B-AD compared to acute B-AD. 23, 35 Ongoing surveillance is clearly critical to identify such complications, although no studies have investigated the optimal frequency and modality of surveillance.
Overall mid-term mortality was 9.2% (46/499), though individual survival rates varied from 59.1 to 100% in studies with a median follow-up of 24 months. The wide range of survival rates reported in the literature (Fig. 2 ) may reflect heterogeneity in case selection, unreported surgical turndown rates, small sample size within existing case series, and the immature nature of the existing evidence base. More robust and plentiful evidence is therefore needed to establish the mid-term safety of TEVAR as an alternative to open repair or best medical therapy, and to characterise which patients derive the greatest benefit. Mid-term health economic data were also not available to facilitate comparison of TEVAR to open repair or conservative management in chronic B-AD. All of the above must be put in to context through the collection and publication of accurate natural history data for aortic type B dissections.
It has been suggested that TEVAR is associated with improved 1-year survival (TEVAR 90e93% vs. open 79e81%) but poorer 3-year survival (TEVAR 67% vs. open 71%) than open repair. 12 In contrast, the INSTEAD trial reported no survival advantage of TEVAR over best medical therapy at 2 years (medical therapy 95.6% vs. TEVAR 88.9%, p Z 0.15); and no improvement in the rate of aortic rupture or the need for endovascular or open re-intervention. 7 However, in favour of TEVAR, the trial demonstrated a significantly greater degree of aortic remodelling after TEVAR (rate of TL patency and FL thrombosis; TEVAR 91.3% vs. medical therapy 19.4%, p < 0.001). 36 These findings are supported by the summary data from the present review, which demonstrate FL reduction in 79.4% (27/34) and TL expansion in 66.1% (41/62) of patients followed-up for a median of 30 months. The median rate of complete FL thrombosis in the literature was 85.7%, similar to the rate observed after TEVAR for acute B-AD (85%), 15 though individual studies varied widely (Fig. 5) .
Although reporting standards have been agreed for endoleak in the context of aneurysmal disease, 19 it has been widely acknowledged that definitions of endoleak from aneurysm reporting criteria are not fully applicable to dissections. 37 Various definitions of type I endoleak were used in reports of TEVAR for chronic B-AD. Some authors defined endoleak as any radiological evidence of flow outside the stent-graft except persistent retrograde FL perfusion, 27 others as flow into the FL due to an ineffective seal at one extremity of the stent-graft, 21 and others as any failure of entry tear closure resulting in continued antegrade FL perfusion. 5 Consensus reporting criteria are required to account for situations unique to dissection such as FL perfusion arising from the left subclavian artery despite an adequate proximal endograft seal, or a persistently patent FL distal to the endograft despite a thrombosed FL at the level of the endograft. 37 Despite a large number of published cohort studies for TEVAR in chronic B-AD, few data were available to assess outcomes up to 5 years. The wide range observed in mortality, re-intervention and major complications reflected the paucity of mid-term data available specifically for TEVAR in chronic B-AD. Reports of long-term results from sources such as the ongoing VIRTUE Registry 38 of Type B thoracic dissections are needed in the world literature to improve our understanding of the treatment of these pathologies.
The potential methodological limitations of this study include the inability to eliminate selection bias from the review. This was due to the vast majority of key papers being retrospective case series, in which the proportions of rejected cases were often not reported. 39 Nevertheless, trends in selection towards age, gender and patient comorbidities were available for summary. Other variations in case reporting (e.g. inconsistent reporting of proportions of indications for TEVAR) also limited further stratification of treatment outcomes. Similarly, the issue of information bias cannot completely be overcome at this stage, as it is Figure 4 Scatterplot to illustrate mid-term incidence of endoleak after TEVAR for chronic type B aortic dissection. Each of the 10 studies is represented by a single datapoint. The sample size of each study (range 10e84) is reflected by the size of its respective datapoint. The reference number of each study is also displayed within the respective datapoint. Figure 5 Scatterplot to illustrate mid-term incidence of complete false-lumen thrombosis after TEVAR for chronic B-AD. Each of the 12 studies is represented by a single datapoint. The sample size of each study (range 14e84) is reflected by the size of its respective datapoint. The reference number of each study is also displayed within the respective datapoint. too early to estimate the proportion of poor TEVAR results that are not published. This is a typical concern of any of such new technology, and provides another incentive for randomised controlled trials of TEVAR in chronic B-AD.
Conclusion
Current evidence demonstrates conflicting outcomes for the use of TEVAR over best medical therapy and open repair for chronic B-AD. The lack of natural history data for cases treated medically or by open repair, significant heterogeneity in case selection and absence of consensus reporting standards for intervention are significant obstructions to interpreting these data, and making robust comparisons of TEVAR against open repair or best medical treatment. Future case series, registries and clinical trials must address each of these aspects in order that we do not do patients a disservice. Mid-to long-term outcome data (e.g. freedom from rupture, aneurysm formation and re-intervention) must be a focus of such studies. High-quality randomised studies are urgently needed.
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